全球抗肥胖藥物市場
市場調查報告書
商品編碼
1389576

全球抗肥胖藥物市場

Global Market for Anti-obesity Drugs

出版日期: | 出版商: BCC Research | 英文 67 Pages | 訂單完成後即時交付

價格

本報告調查了全球抗肥胖藥物市場,並提供了市場概況和背景、市場影響因素和市場機會分析、市場規模趨勢和預測、各個細分市場和地區的詳細分析、ESG競爭形勢、主要企業概況等

目錄

第1章 簡介

第2章 摘要/亮點

  • 市場展望
  • 市場摘要

第3章 市場概況

  • 成人肥胖和超重的定義
  • 超重和肥胖相關疾病
  • 肥胖盛行率上升
  • 肥胖對全球經濟的影響
  • 提高人們對肥胖的認知
  • SWOT分析

第4章 全球抗肥胖藥物市場:依類型

  • 處方藥
  • 非處方藥

第5章 全球抗肥胖藥物市場:依配銷通路

  • 醫院藥房
  • 零售藥房
  • 線上藥房

第6章 全球抗肥胖藥物市場:依地區

  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

第7章 ESG發展

  • ESG:概述
  • ESG 在抗肥胖藥物產業的重要性
  • ESG 是抗肥胖藥物產業的支柱
  • 環境指標
  • 社會指標
  • 管治指標
  • ESG 評級和指標:了解資料
  • ESG在抗肥胖藥物產業的實踐
  • 環保性能
  • 社會表現
  • 管治績效
  • BCC的結語

第8章 競爭形勢

  • 概述
  • 管道分析
  • 肥胖管理相關專利

第9章 公司簡介

  • ALTIMMUNE INC.
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • CURRAX PHARMACEUTICALS LLC
  • ELI LILLY AND CO.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • NOVO NORDISK A/S
  • PFIZER INC.
  • RHYTHM PHARMACEUTICALS, INC.
  • VIVUS LLC
Product Code: PHM281A

Highlights:

This report provides an overview of the global market on anti-obesity drugs and an analysis of global market trends, using 2022 as the base year and forecasting 2023 through 2028 with a compound annual growth rate (CAGR) projection. The report details the anti-obesity drugs market based on drug type, distribution channel, and region.

Report Scope:

The report's scope includes an overview of the global market for anti-obesity drugs and an analysis of global market trends, using 2022 as the base year and forecasting 2023 through 2028 with a compound annual growth rate (CAGR) projection.

The report analyzes anti-obesity drugs by drug types, assesses distribution channels, and provides an overview regarding product pipeline of major players in market. Leading market players' profiles, marketed products, pipeline products, and recent market activities are provided. The report details market for anti-obesity drugs based on drug type, distribution channel, and region. Based on drug type, the market is segmented into prescription drugs, and over-the-counter (OTC) drugs. The market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies on the basis of distribution channel. Regional analysis includes North America (U.S., Canada, Mexico), Europe (U.K., Germany, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the world (South America, and the Middle East and Africa).

Report Includes:

  • An overview of the current and future global markets for anti-obesity drugs
  • Analyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Estimate of the actual market size and revenue forecast for the global anti-obesity drugs market, and corresponding market share analysis based on drug type, distribution channel, and region
  • Overview of ESG outlook with emphasis on sustainability trends and factors on anti-obesity drugs market
  • Identification of the major vendors in the global market for anti-obesity drugs, along with an analysis of the structure of this industry, including company market shares, M&A deals and venture fundings
  • Profiles of the leading global players

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Research Methodology
  • Information Sources
  • Geographic Breakdown
  • Segmentation Breakdown

Chapter 2 Summary and Highlights

  • Market Outlook
  • Market Summary

Chapter 3 Market Overview

  • Definitions of Adult Obesity and Overweight
  • Overweight- and Obesity-Related Diseases
  • Rising Prevalence of Obesity
  • Impact of Obesity on Global Economy
  • Increasing Awareness Regarding Obesity
  • SWOT Analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats

Chapter 4 Global Market for Anti-obesity Drugs by Type

  • Prescription Drugs
  • Over-the-Counter Anti-obesity Drugs

Chapter 5 Global Market for Anti-obesity Drugs by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Chapter 6 Global Market for Anti-obesity Drugs by Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 7 ESG Developments

  • Introduction to ESG
  • Importance of ESG in Anti-obesity Drugs Industry
  • ESG Pillars in the Anti-obesity Drug Industry
  • Environmental Metrics
  • Social Metrics
  • Governance Metrics
  • ESG Ratings and Metrics: Understanding the Data
  • ESG Practices in the Anti-obesity Drug Industry
  • Environmental Performance
  • Social Performance
  • Governance Performance
  • Concluding Remarks from BCC

Chapter 8 Competitive Landscape

  • Overview
  • Pipeline Analysis
  • Patents on Obesity Management, 2020-2023

Chapter 9 Company Profiles

  • ALTIMMUNE INC.
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • CURRAX PHARMACEUTICALS LLC
  • ELI LILLY AND CO.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • NOVO NORDISK A/S
  • PFIZER INC.
  • RHYTHM PHARMACEUTICALS, INC.
  • VIVUS LLC

List of Tables

  • Summary Table : Global Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
  • Table 1 : Definitions of Adult Obesity and Overweight
  • Table 2 : Number of People, Aged Over 5 Years, and Percentage of the Population With Overweight or Obesity, 2020-2035
  • Table 3 : Global Obesity Trends for Children and Adolescents, Aged 5 to 19 Years, by Gender, 2020-2035
  • Table 4 : Global Obesity Trends for Adults, Aged 20 Years and Above, by Gender, 2020-2035
  • Table 5 : Global Economic Impact of High BMI (BMI ≥25kg/m²), 2020-2035
  • Table 6 : Global Market for Anti-obesity Drugs, by Drug Type, Through 2028
  • Table 7 : Difference between Prescription Drugs and Over-the-Counter Anti-obesity Drugs
  • Table 8 : Approved Prescription Drugs to Treat Overweight and Obesity
  • Table 9 : Global Market for Anti-obesity Prescription Drugs, by Region, Through 2028
  • Table 10 : Global Market for Over-the-Counter Anti-obesity Drugs, by Region, Through 2028
  • Table 11 : Global Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
  • Table 12 : Global Market for Anti-obesity Drugs Sold through Hospital Pharmacies, by Region, Through 2028
  • Table 13 : Global Market for Anti-obesity Drugs Sold through Retail Pharmacies, by Region, Through 2028
  • Table 14 : Global Market for Anti-obesity Drugs Sold through Online Pharmacies, by Region, Through 2028
  • Table 15 : Global Market for Anti-obesity Drugs, by Region, Through 2028
  • Table 16 : North American Market for Anti-obesity Drugs, by Drug Type, Through 2028
  • Table 17 : North American Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
  • Table 18 : European Market for Anti-obesity Drugs, by Drug Type, Through 2028
  • Table 19 : European Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
  • Table 20 : Asia-Pacific Market for Anti-obesity Drugs, by Drug Type, Through 2028
  • Table 21 : Asia-Pacific Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
  • Table 22 : Rest of the World Market for Anti-obesity Drugs, by Drug Type, Through 2028
  • Table 23 : Rest of the World Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
  • Table 24 : ESG Ratings and Metrics
  • Table 25 : Environmental Performance
  • Table 26 : Social Performance
  • Table 27 : Governance Performance
  • Table 28 : ESG Rankings for Major Anti-obesity Drug Companies, 2023*
  • Table 29 : Anti-obesity Drugs in Clinical Trials, 2023
  • Table 30 : Patents on Obesity Management, 2020-2023
  • Table 31 : Altimmune: Pipeline Products
  • Table 32 : Altimmune: News, 2023
  • Table 33 : Boehringer Ingelheim: Pipeline Products
  • Table 34 : Boehringer Ingelheim: News, 2023
  • Table 35 : Currax Pharmaceuticals LLC: Products
  • Table 36 : Currax Pharmaceuticals LLC: News, 2022
  • Table 37 : Eli Lilly: Pipeline Products
  • Table 38 : Eli Lilly: News, 2023
  • Table 39 : ROCHE: Products
  • Table 40 : GlaxoSmithKline: Products
  • Table 41 : Novo Nordisk A/S: Products
  • Table 42 : Novo Nordisk A/S: Pipeline Products
  • Table 43 : Novo Nordisk A/S: News, 2023
  • Table 44 : Pfizer: Pipeline Products
  • Table 45 : Pfizer: News, 2023
  • Table 46 : Rhythm Pharmaceuticals: Products
  • Table 47 : Rhythm Pharmaceuticals: Pipeline Products
  • Table 48 : Rhythm Pharmaceuticals: News, 2023
  • Table 49 : VIVUS LLC: Products
  • Table 50 : VIVUS LLC: News, 2023

List of Figures

  • Summary Figure : Global Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
  • Figure 1 : Global Market for Anti-obesity Drugs: SWOT Analysis
  • Figure 2 : Global Market for Anti-obesity Drugs, by Drug Type, 2021-2028
  • Figure 3 : Global Market for Anti-obesity Prescription Drugs, by Region, 2021-2028
  • Figure 4 : Global Market for Over-the-Counter Anti-obesity Drugs, by Region, 2021-2028
  • Figure 5 : Global Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
  • Figure 6 : Global Market for Anti-obesity Drugs Sold through Hospital Pharmacies, by Region, 2021-2028
  • Figure 7 : Global Market for Anti-obesity Drugs Sold through Retail Pharmacies, by Region, 2021-2028
  • Figure 8 : Global Market for Anti-obesity Drugs Sold through Online Pharmacies, by Region, 2021-2028
  • Figure 9 : Global Market Shares of Anti-obesity Drugs, by Region, 2023
  • Figure 10 : North American Market for Anti-obesity Drugs, by Drug Type, 2021-2028
  • Figure 11 : North American Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
  • Figure 12 : European Market for Anti-obesity Drugs, by Drug Type, 2021-2028
  • Figure 13 : European Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
  • Figure 14 : Asia-Pacific Market for Anti-obesity Drugs, by Drug Type, 2021-2028
  • Figure 15 : Asia-Pacific Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
  • Figure 16 : Rest of the World Market for Anti-obesity Drugs, by Drug Type, 2021-2028
  • Figure 17 : Rest of the World Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028